Practice case - Oldpharma
Context
The interviewer will typically start the case by giving a brief overview of the
context, ending with a question that is the problem definition. At the end of the
description. you will have an opportunity to ask any questions you might have to
clarify the information that has been provided to you.
Client goal
Our client is OldPharma, a major pharmaceutical company (pharmaco) with
USD 10 billion a year in revenues. Its corporate headquarters and primary
research and development (R&D) centers are in Germany, with regional sales
offices worldwide.
Description of OldPharma
Let’s assume our client is 0IdPharma, a major pharmaceutical company
(pharmaco) with USD 10 billion a year in revenues. Its corporate headquarters
and primary research and development (R&D) centers are in Germany, with
regional sales offices worldwide.
OIdPharma has a long, successful tradition in researching, developing, and
selling “small molecule" drugs. This class of drugs represents the vast majority
of drugs today, including aspirin and most blood-pressure or cholesterol
medications. 0IdPharma is interested in entering a new, rapidly growing
segment of drugs called “biologicals.” These are often proteins or other large,
complex molecules that can treat conditions not addressable by traditional drugs.
Biological R&D is vastly different from small molecule R&D. To gain these
capabilities, pharmacos can build them from scratch, partner with existing
startups, or acquire them. Since its competitors are already several years ahead
of OldPharma, OldPharma wants to jumpstart its biologicals program by
acquiring BioFuture, a leading biologicals start-up based in the San Francisco
area. BioFuture was founded 12 years ago by several prominent scientists and
now employs 200 people. It is publicly traded and at its current share price the
company is worth about USD 1 billion in total.
OldPharma has engaged McKinsey to evaluate the BioFuture acquisition and
advise on its strategic fit with OldPharma's biologicals strategy.
Should 0IdPharma acquire BioFuture?
Practice case - Oldpharma
Context
The interviewer will typically start the case by giving a brief overview of the
context, ending with a question that is the problem definition. At the end of the
description. you will have an opportunity to ask any questions you might have to
clarify the information that has been provided to you.
Client goal
Our client is OldPharma, a major pharmaceutical company (pharmaco) with
USD 10 billion a year in revenues. Its corporate headquarters and primary
research and development (R&D) centers are in Germany, with regional sales
offices worldwide.
Description of OldPharma
Let’s assume our client is 0IdPharma, a major pharmaceutical company
(pharmaco) with USD 10 billion a year in revenues. Its corporate headquarters
and primary research and development (R&D) centers are in Germany, with
regional sales offices worldwide.
OIdPharma has a long, successful tradition in researching, developing, and
selling “small molecule" drugs. This class of drugs represents the vast majority
of drugs today, including aspirin and most blood-pressure or cholesterol
medications. 0IdPharma is interested in entering a new, rapidly growing
segment of drugs called “biologicals.” These are often proteins or other large,
complex molecules that can treat conditions not addressable by traditional drugs.
Biological R&D is vastly different from small molecule R&D. To gain these
capabilities, pharmacos can build them from scratch, partner with existing
startups, or acquire them. Since its competitors are already several years ahead
of OldPharma, OldPharma wants to jumpstart its biologicals program by
acquiring BioFuture, a leading biologicals start-up based in the San Francisco
area. BioFuture was founded 12 years ago by several prominent scientists and
now employs 200 people. It is publicly traded and at its current share price the
company is worth about USD 1 billion in total.
OldPharma has engaged McKinsey to evaluate the BioFuture acquisition and
advise on its strategic fit with OldPharma's biologicals strategy.
Should 0IdPharma acquire BioFuture?
การแปล กรุณารอสักครู่..